Abstract

Pulmonary carcinoids (PCs) display the common features of all well-differentiated neuroendocrine neoplasms (NEN) and are classified as low- and intermediate-grade malignant tumours (i.e., typical and atypical carcinoid, respectively). There is a paucity of randomised studies dedicated to advanced PCs and management principles are drawn from the larger gastroenteropancreatic NEN experience. There is growing evidence that NEN anatomic subgroups have different biology and different responses to treatment and, therefore, should be investigated as separate entities in clinical trials. In this review, we discuss the existing evidence and limitations of tumour classification, diagnostics and staging, prognostication, and treatment in the setting of PC, with focus on unmet medical needs and directions for the future.

Original languageEnglish
Pages (from-to)7-17
Number of pages11
JournalNeuroendocrinology
Volume108
Issue number1
Early online date24 Sept 2018
DOIs
Publication statusPublished - 2019

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms'. Together they form a unique fingerprint.

Cite this